BioWorld Today here continues its occasional listings of government agencies seeking industrial licensees to commercialize biotechnology-related research and development. Commercialization rights are offered by the National Institutes of Health, Office of Technology Transfer (OTT).

Announcements of the following two Cooperative Research and Development Agreement (CRADA) partnerships (see National Cancer Institute listings) and 10 licensing opportunities have been submitted recently to the Federal Register.

To obtain CRADA or licensing information, and copies of the U.S. patent issuances or applications listed below, contact the OTT licensing specialists indicated.

FOOD & DRUG ADMINISTRATION

Lipopolysaccharide Carriers For Vaccines

Brucella abortus lipopolysaccharides allow the generation of antibody responses in a T cell-independent manner. When used as a carrier for antigens from infectious agents or tumors, the conjugate formed has less tendency to induce inflammatory cytokines and subsequent endotoxic shock.

Application: 08/369,565

Filed: 1/6/95

Inventors: Golding, B.

Contact: Robert Benson, (301) 496-7056, ext. 267

NATIONAL CANCER INSTITUTE

Antitumor Macrocyclic Lactones

Macrocyclic lactones, which are based on compounds isolated from marine sponges and tunicates, have in vitro activity against solid tumors, including non-small cell lung cancer, renal carcinoma, and melanoma. These lactones appear to exert their cellular effects by a novel mechanism of action, making them potentially useful therapeutics for cancers resistant to currently used drugs.

Application: 60/053,784

Filed: 6/29/97

Inventors: Boyd, M., et al.

Contact: Girish C. Barua, (301) 496-7056, ext. 263

Attenuated HIV Strain Vaccines

Attenuated HIV strains lack functional virus-derived nucleo-cytoplasmic transport elements, which are part of every RNA encoding structural gene. By replacing such mutated elements with those derived from mice, the ability of the virus to replicate is between 50 and 100 times less than that of wild type strains, thus making the mutated strains suitable for vaccines.

Application: 60/070,204

Filed: 12/31/97

Inventors: Felber, B.K., et al.

Contact: Robert Benson, (301) 496-7056, ext. 267

Non-Replicating HIV Mimics

When the conserved amino acid motif found in the nucleocapsid domain of retroviral gag precursor proteins is mutated, the resulting virions have much lower or zero infectivity. When this concept was tested in monkeys with simian immunodeficiency virus (SIV), animals vaccinated with strains mutated in this manner were partially or fully protected from subsequent SIV challenge. Similar non-infectious, non-replicating HIV strains are available for testing as vaccine candidates.

U.S. Patent: 5,674,720

Issued: 10/7/97

Inventors: Gorelick, R.J., et al.

Contact: Robert Benson, (301) 496-7056, ext. 267

Cancer Chemotherapeutic

Demethylpenclomedine, a derivative of the promising new cancer chemotherapeutic penclomedine, shows reduced dose-limiting side effects in animal models in comparison to the parent compound. Its reduced toxicity profile may allow demethylpenclomedine use at higher levels than penclomedine, thus allowing targeting of hard-to-treat cancers.

Application: 60/019,086

Filed: 6/3/96

Inventors: Hartman, N., et al.

Contact: Girish C. Barua, (301) 496-7056, ext. 263

Fusion Immunotoxin For Graft Rejection

A recombinant immunotoxin that is able to kill activated T cells causing graft rejection when used at very low concentration is undergoing animal and clinical testing. This immunotoxin is a single chain protein having a T cell-targeting Fv portion of an antibody fused to the amino terminus of Pseudomonas exotoxin A. Animal tests show reduced graft rejection after bone marrow transplantation. Phase I trials in humans show that this immunotoxin can be safely administered intravenously.

The NCI seeks partners to further evaluate and develop the clinical and commercial potential of this immunotoxin for the prevention of graft-versus-host disease. CRADA proposals should be received on or before 90 days after publication of this notice in the Federal Register for priority consideration. However, CRADA proposals submitted thereafter may be considered if a suitable collaborator has not been selected.

U.S. Patent: 4,892,827

Issued: 1/9/90

Inventors: Pastan, I.H., et al.

Contact: J.R. Dixon, (301) 496-7056, ext. 206

Fusion Immunotoxin For Ovarian Cancer

A recombinant immunotoxin that targets mesotheliomas, which are resistant to chemotherapy, is undergoing animal testing. This immunotoxin is a single chain protein having a mesothelioma-targeting Fv portion of an antibody fused to a mutant Pseudomonas exotoxin A via a disulfide linkage. Tests in mice show complete tumor regression without death or toxicity. Toxicity tests in monkeys show transient liver enzyme elevation and inactivity followed by full recovery.

The NCI seeks partners to further evaluate and develop the clinical and commercial potential of this immunotoxin for the treatment of mesotheliomas. CRADA proposals should be received on or before 90 days after publication of this notice in the Federal Register for priority consideration. However, CRADA proposals submitted thereafter may be considered if a suitable collaborator has not been selected.

Application: 08/776,271

Filed: 1/21/97

Inventors: Pastan, I.H., et al.

Contact: J.R. Dixon, (301) 496-7056, ext. 206

NATIONAL INSTITUTE ON ALCOHOL ABUSE & ALCOHOLISM

Central Serotonin Function Assay

Levels of salivary prolactin correlate with cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid, the current measurement of central serotonin functioning. Variations in CSF serotonin levels appear to determine the potential susceptibility of individuals to psychiatric problems, such as violent behavior, alcohol abuse, and obsessive-compulsive and eating disorders. Thus, a simple and cost-effective salivary prolactin test may allow for mass screening to determine susceptibility to such disorders.

Application: 60/082,126

Filed: 4/16/98

Inventors: Higley, J.D., et al.

Contact: Stephen Finley, (301) 496-7735, ext. 215

NATIONAL INSTITUTE OF CHILD HEALTH & DEVELOPMENT

Salmonella Conjugate Vaccine

A conjugate vaccine against Salmonella paratyphi, a cause of enteritis and enteric fever, has detoxified o-specific lipopolysaccharide conjugated to a carrier protein, such as tetanus toxoid. In Phase I clinical trials, this vaccine causes the induction of fourfold higher blood anti-Salmonella antibody levels. This vaccine may combat the emergence of multidrug resistant strains of the bacterium.

Application: PCT/US96/19978

Filed: 12/18/96

Inventors: Konadu, E., et al.

Contact: Robert Benson, (301) 496-7056, ext. 267

NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

Glucocorticoid-Regulated Gene Expression

The glucocorticoid modulatory element in glucocorticoid-inducible genes has two identified binding proteins. These proteins have been successfully characterized and their genes cloned. Since modulators that bind the glucocorticoid modulatory element cause hormone induction of transcription at a lower steroid concentration than normal, the development of therapeutics for selective regulation of glucocorticoid-responsive genes that are based on these proteins may be possible.

DHHS Reference: E-070-97/0

Filed: 7/25/97

Inventors: Simons, S.S., et al.

Contact: Charles Maynard, (301) 496-7735, ext. 243

Radiofrequency Preamplifier For Magnetic Resonance Imaging

A radiofrequency preamplifier with very fast recovery after the transmit cycle allows ultrafast data acquisition. When used for pulsed electron paramagnetic resonance, magnetic resonance imaging, and other computed imaging techniques, a device having this type of preamplifier permits the use of lower frequencies, which offer better tissue penetration during in vivo diagnostic studies. A constructed prototype device offers improved speed and sensitivity over existing methods.

Application: 08/699,383

Filed: 8/19/96

Inventors: Tschudin, R.G., et al.

Contact: John Fahner-Vihtelic, (301) 496-7735, ext. 270

NATIONAL INSTITUTE OF NEUROLOGICAL DISEASE & STROKE

Oral Feeding of Myelin Basic Protein for Stroke Resistance

In vivo experiments show that immunosuppression in the brain can be achieved through the induction of tolerance by oral feeding of basic myelin protein. After this treatment, immune cells are relatively unreactive to this protein, which is released as a result of neuronal damage from stroke. Thus, this therapeutic treatment, which does not have the detrimental side effects of other immunosuppressants, may minimize the severity of damage from stroke when administered to populations at risk.

Application: 08/994,293

Filed: 12/19/97

Inventors: Becker, K.J., et al.

Contacts: Stephen Finley, (301) 496-7735, ext. 215

— Compiled by Chester Bisbee